Acrivon Therapeutics (NASDAQ:ACRV) Downgraded by LADENBURG THALM/SH SH

LADENBURG THALM/SH SH cut shares of Acrivon Therapeutics (NASDAQ:ACRV) from a buy rating to a neutral rating in a report published on Monday morning, Marketbeat.com reports.

Several other equities analysts also recently commented on ACRV. JMP Securities upped their price target on shares of Acrivon Therapeutics from $14.00 to $17.00 and gave the company a market outperform rating in a research note on Thursday, April 25th. Piper Sandler increased their price objective on shares of Acrivon Therapeutics from $26.00 to $30.00 and gave the stock an overweight rating in a research note on Thursday, April 25th. BMO Capital Markets increased their price objective on shares of Acrivon Therapeutics from $18.00 to $25.00 and gave the stock an outperform rating in a research note on Friday, April 26th. Finally, HC Wainwright reiterated a buy rating and set a $20.00 price objective on shares of Acrivon Therapeutics in a research note on Thursday, April 25th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of Moderate Buy and an average target price of $22.63.

Acrivon Therapeutics Price Performance

NASDAQ:ACRV opened at $8.23 on Monday. Acrivon Therapeutics has a one year low of $3.19 and a one year high of $14.30. The company has a market cap of $186.33 million, a P/E ratio of -3.01 and a beta of 1.94. The firm’s fifty day moving average price is $6.87 and its two-hundred day moving average price is $5.39.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings data on Thursday, March 28th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.72) by ($0.14). As a group, equities research analysts expect that Acrivon Therapeutics will post -3.16 earnings per share for the current year.

Insider Activity at Acrivon Therapeutics

In other Acrivon Therapeutics news, major shareholder Perceptive Advisors Llc acquired 2,353,000 shares of the company’s stock in a transaction that occurred on Thursday, April 11th. The stock was acquired at an average price of $8.50 per share, for a total transaction of $20,000,500.00. Following the acquisition, the insider now directly owns 5,360,858 shares in the company, valued at $45,567,293. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 7.30% of the stock is owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Acrivon Therapeutics stock. Exchange Traded Concepts LLC lifted its position in shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) by 34.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 13,289 shares of the company’s stock after buying an additional 3,370 shares during the quarter. Exchange Traded Concepts LLC owned about 0.06% of Acrivon Therapeutics worth $65,000 at the end of the most recent reporting period. 71.62% of the stock is owned by institutional investors and hedge funds.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.